Results 181 to 190 of about 83,984 (282)

Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open‐label prospective study

open access: yesEpilepsia Open, Volume 11, Issue 2, Page 466-474, April 2026.
Abstract Objective CDKL5 deficiency disorder (CDD) is an early‐onset developmental and epileptic encephalopathy characterized by frequent drug‐resistant seizures, cerebral visual impairment, motor dysfunction, and sleep and gastrointestinal disturbances.
Marco Perulli   +12 more
wiley   +1 more source

Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathy. [PDF]

open access: yesHepatol Commun
Jesudian AB   +7 more
europepmc   +1 more source

Opportunities and costs of clinical research. [PDF]

open access: yes, 1985
Gavaler, JS   +3 more
core   +1 more source

Rifaximin Use Is Associated With Prognosis and Recurrence Patterns in Spontaneous Bacterial Peritonitis: Exploratory Insights Into the Oral–Gut–Hepatic Axis

open access: yesJGH Open, Volume 10, Issue 4, April 2026.
ABSTRACT Background Spontaneous bacterial peritonitis (SBP) remains a life‐threatening complication in cirrhotic patients with refractory ascites. Evidence for rifaximin (RFX) in SBP prevention and prognosis is lacking in Japan. We investigated the effect of RFX on prognosis and recurrence of SBP and evaluated the prognostic role of oral health within ...
Yoshihito Uchida   +10 more
wiley   +1 more source

Nurse‐Led Clinic for Patients With Decompensated Liver Cirrhosis

open access: yesJGH Open, Volume 10, Issue 4, April 2026.
ABSTRACT Background and Aims Prognosis for patients with decompensated liver cirrhosis is poor and readmissions are frequent. Closer and more structured follow‐up by nurses may prevent readmissions and stabilize liver‐related complications. We aimed to test the hypothesis that establishing a nurse‐led clinic for patients with decompensated liver ...
Elsebeth E. Kelstrup   +5 more
wiley   +1 more source

S100B protein as a marker of minimal hepatic encephalopathy. [PDF]

open access: yesPrz Gastroenterol
Pisarek W   +2 more
europepmc   +1 more source

Real‐World Effectiveness of Tolvaptan for Hyponatremia in Cirrhosis Across Global Regions: A Target Trial Emulation

open access: yesJGH Open, Volume 10, Issue 4, April 2026.
ABSTRACT Background Tolvaptan promotes electrolyte‐free water excretion and is widely used in Asia for ascites, but in Western countries its use is limited to hyponatremia because of hepatotoxicity concerns. Methods We performed a retrospective cohort study using the TriNetX Research Network, emulating a target trial of cirrhotic patients with ...
Kazuya Okushin   +5 more
wiley   +1 more source

Differential Mortality Risk by Age in Males and Females With Steatotic Liver Disease

open access: yesMedComm, Volume 7, Issue 4, April 2026.
Data on the impact of sex for overall and cause‐specific mortality in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) is limited. Among older (>50 years) people with MASLD, males had about 40% higher risk of overall and nonliver related mortality, while the opposite was observed with females having about 30% higher risk ...
Taotao Yan   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy